Clinical Trial Update: Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis [Phase 2]

View source ↗

Summary

Phase 2 trial of JBT-101 in dermatomyositis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• JBT-101

Snippet

Sponsor: Corbus Pharmaceuticals Inc. | Conditions: Dermatomyositis | Phase 2 | Status: TERMINATED | Results posted: 2023-01-19